Check out our press release hub, powered by Business Wire. It's a one stop shop for industry announcements to help you stay on top of the latest technology and investment trends. Get the scoop here.
HONOLULU–(BUSINESS WIRE)–April 22, 2014–
Cardax, Inc. (“Cardax” or the “Company”) (OTCQB: CDXI) was featured recently in an in-depth article in the March 2014 issue of Hawaii Business, Hawaii’s leading business magazine, titled: “Hawaii-Born Pill: The Next Wonder Drug?” It was written by senior reporter Dennis Hollier.
The article can be found at: http://www.hawaiibusiness.com/Hawaii-Business/March-2014/Can-a-Hawaii-Company-Produce-the-Next-Wonder-Drug
About Hawaii Business
Founded in 1955, Hawaii Business is currently the oldest regional business magazine in America. The magazine’s editorial content focuses on big issues concerning the state’s major industries: tourism, construction, agriculture and real estate. The SmallBiz section, which runs every month, covers Hawaii’s small businesses. Throughout the year, Hawaii Business produces business events and seminars aimed at the business community, with specific events tied to the signature issues. Events range from awards, to honoring specific individuals, to informative and educational forums and symposiums.
Cardax is a development stage life sciences company that devotes substantially all of its efforts to developing nutraceutical and pharmaceutical products that provide the anti-inflammatory benefits of steroids or NSAIDS, but with exceptional safety profiles, as conferred by U.S. Food and Drug Administration (“FDA”) Generally Recognized as Safe (“GRAS”) designation at certain doses. Cardax is preparing proprietary nature-identical products and related derivatives by total synthesis to provide scalable, pure, and economical therapies for diseases where inflammation and oxidative stress are strongly implicated, including, but not limited to, osteoarthritis, rheumatoid arthritis, dyslipidemia, metabolic disease, diabetes, cardiovascular disease, hepatitis, cognitive decline, macular degeneration, and prostate disease. The initial primary focus of Cardax is its astaxanthin technologies. Astaxanthin is a powerful and safe naturally occurring anti-inflammatory and anti-oxidant without the adverse side effects typical of anti-inflammatory treatments using steroids or NSAIDS, including immune system suppression, liver damage, cardiovascular disease risk, and gastrointestinal bleeding.
This release may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of said safe harbor provisions.
Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of our company, are generally identified by use of words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “project,” “seek,” “strive,” “try,” or future or conditional verbs such as “could,” “may,” “should,” “will,” “would,” or similar expressions. Our ability to predict results or the actual effects of our plans or strategies is inherently uncertain. Accordingly, actual results may differ materially from anticipated results. Some of the factors that could cause our actual results to differ from our expectations or beliefs include, without limitation, the risks discussed from time to time in our filings with the Securities and Exchange Commission.
Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Except as required by applicable law or regulation, we undertake no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made.
Janice Kam, 808-457-1400
VentureBeat’s VB Insight team is studying email marketing tools.
Chime in here, and we’ll share the results